Navidea, Hainan Sinotau Pharmaceutical deal

Navidea granted Hainan Sinotau exclusive rights in China, excluding Hong Kong and Macau, to develop and commercialize Lymphoseek tilmanocept. Navidea will receive $300,000 up front and is eligible for up to $700,000 in milestones through product approval and $1.5 million in sales milestones, plus undisclosed royalties. The companies will jointly support premarket planning activities on clinical and market development programs. Sinotau will be responsible for costs and conduct of clinical trials, regulatory submissions and commercialization. ...